Evaluation of the Effectiveness of the Additional Risk Minimisation Measures for Hemgenix®: PASS Survey Among Physicians in European Countries

Study type

• Study topic:
  Human medicinal product
• Study type:
  Non-interventional study
• Scope of the study:
  Assessment of risk minimisation measure implementation or effectiveness
• Data collection methods:
  Primary data collection

Study drug and medical condition

• Medicinal product name:
  HEMGENIX
• Study drug International non-proprietary name (INN) or common name:
  ETRANACOGENE DEZAPARVOVEC
• Anatomical Therapeutic Chemical (ATC) code:
  (B02BD16) etranacogene dezaparvovec

  etranacogene dezaparvovec

Population studied

• Short description of the study population:
  physicians involved or potentially involved in Hemgenix prescription, administration and/or post-treatment monitoring